Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* tuberculosis cases~* treated with isoniazid, rifampicin, ethambutol and pyrazinamide~Exclusion Criteria:~* no known liver disease (HBV, HCV), and HIV infection~* normal ALT level before enrollment~* refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- silymarin (Type: ACTIVE_COMPARATOR): Silymarin 140 mg three times a day for 4 weeks
- placebo (Type: PLACEBO_COMPARATOR): Placeo~1 tab three times a day for 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).